KOSÉ (4922) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
14 May, 2026Executive summary
Net sales for 1Q 2026 were ¥78,265 million, down 0.9% year-over-year, mainly due to lower ALBION and KOSÉ Cosmeport sales, partially offset by growth at Tarte and KOSÉ.
Operating profit dropped 84.5% to ¥1,030 million, impacted by lower earnings at ALBION, KOSÉ Cosmeport, and Tarte, and the absence of prior-year asset sale gains.
Profit attributable to owners of parent fell 91.9% to ¥426 million, reflecting the absence of prior-year gains from asset sales and higher promotional expenses.
Overseas sales accounted for 38.5% of total sales, with strong growth in Asia and North America offsetting declines in Japan.
Comprehensive income declined 80.3% to ¥495 million.
Financial highlights
Gross profit decreased to ¥54,609 million, with gross margin falling to 69.8%.
Net income per share dropped from ¥92.75 to ¥7.48 year-over-year.
SG&A expenses rose 7.3% to ¥53.5 billion, with notable increases in advertising and marketing costs.
Cost of sales ratio increased from 28.3% to 30.2%.
Operating profit margin fell to 1.3% from 8.4% in 1Q 2025.
Outlook and guidance
FY2026 sales are forecast to rise 6.0% to ¥350,000 million, with operating profit planned at ¥21,000 million (+2.2% YoY), and profit attributable to owners of parent at ¥12,100 million (+19.9%).
Net income per share is projected at ¥212.67 for FY2026.
Growth expected across core companies in Japan, Tarte, and PURI, despite anticipated cost increases.
No revisions to previously announced guidance.
Latest events from KOSÉ
- FY2025 delivered higher sales and profit, with FY2026 targeting further growth but lower net income.4922
Q4 202512 Feb 2026 - Sales up slightly, but profit down on higher costs and FX losses; full-year outlook maintained.4922
Q3 202510 Nov 2025 - Operating profit fell 17.7% as higher costs and FX losses offset modest sales growth.4922
Q2 20257 Aug 2025 - Double-digit profit growth led by Japan and North America, while China lags.4922
Q2 202413 Jun 2025 - Sales growth offset by China restructuring loss; profit outlook cut, dividend steady.4922
Q3 202413 Jun 2025 - Sales up, profits down; 2025 outlook positive despite cost and FX headwinds.4922
Q1 20256 Jun 2025 - 2024 profit fell on China reforms, but 2025 outlook is for strong recovery and sales growth.4922
Q4 20246 Jun 2025